Document:

EX-10.29

 Exhibit 10.29 

Confidential Materials omitted and filed separately with the 

Securities and Exchange Commission. Double asterisks denote omissions. 

Execution Document 

AMENDMENT 
 TO 

COLLABORATION AND LICENSE AGREEMENT 

This Amendment to the Collaboration and License Agreement (this “Amendment”) is dated as of October 8, 2013 (the
“Amendment Effective Date”) by and among Epizyme, Inc. (“EPIZYME”), Celgene International Sàrl (“CELGENE”) and Celgene Corporation (“PARENT”). Each of EPIZYME and CELGENE may be referred to
herein as a “Party” or EPIZYME and CELGENE may be referred to herein collectively as the “Parties.” 

WHEREAS, EPIZYME, CELGENE and PARENT entered into the Collaboration and License Agreement as of April 2, 2012 (the
“Agreement”); 
 WHEREAS, the Parties desire to provide for the evaluation of certain compounds of CELGENE and its
Affiliates as potential inhibitors of the Target [**] that may become Compounds and CELGENE Provided Compounds under the Agreement as described in this Amendment; and 

WHEREAS, in order to provide for the aforementioned evaluation, the Parties have determined that solely for the purpose of such evaluation
(and not for evaluations of any other potential CELGENE Provided Compounds), the Parties desire to use a modified version of the evaluation process set forth in Section 2.2.2(a)(iii) of the Agreement, which modified process is described in this
Amendment. 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the
Parties, intending to be legally bound, hereby agree as follows: 
 1. Definitions. Capitalized terms used but not otherwise defined
herein shall have the meanings ascribed to such terms in the Agreement. 
 2. Scope of Amendment. The modified evaluation process set
forth in this Amendment will be used by the Parties, in lieu of the process set forth in Section 2.2.2(a)(iii) of the Agreement, only for the evaluation of existing compounds of CELGENE and its Affiliates identified via screening by CELGENE in
a [**] assay (% inhibition at a single concentration), as potential hits against [**]. For the avoidance of doubt, however, nothing in this Amendment modifies any of CELGENE’s obligations or EPIZYME’s rights under Section 7.1.1 of the
Agreement or constitutes a waiver by EPIZYME with respect thereto. The Parties have, prior to the Amendment Effective Date, identified through their respective scientific designees the compounds of CELGENE and its Affiliates for which the evaluation
process set forth in this Amendment will be used. Such compounds of CELGENE and its Affiliates shall be referred to herein as the “Pre-Collaboration Existing CELGENE [**] Compounds”. For the avoidance of doubt, however, as of
the Amendment Effective Date neither EPIZYME nor EPIZYME’s scientific designees know the identity or structures of the Pre-Collaboration Existing CELGENE [**] Compounds. 

3. Modified Evaluation Process. In lieu of the evaluation process set forth in Section 2.2.2(a)(iii) of the Agreement, the Parties
shall use the following process to evaluate the Pre-Collaboration Existing CELGENE [**] Compounds for potential inclusion in the Collaboration as Compounds and CELGENE Provided Compounds: 

a. CELGENE will provide to EPIZYME Pre-Collaboration Existing CELGENE [**] Compounds in assay-ready plate format for evaluation at EPIZYME
(specific format to be specified by [**]); 

 b. EPIZYME may screen such Pre-Collaboration Existing CELGENE [**] Compounds in the EPIZYME [**]
biochemical assay (% inhibition at a single concentration); 
 c. For those Pre-Collaboration Existing CELGENE [**] Compounds that EPIZYME
identified as hits against the [**] Target through the screening set forth in clause b above (each of which shall be deemed to be an “Initial Hit”), CELGENE may, in its sole discretion, provide additional compound for IC50
determination and testing for [**] activity by EPIZYME in an assay format mutually agreed by EPIZYME and CELGENE; 
 d. Following
EPIZYME’S performance of the IC50 determination and testing for [**]activity described in clause c above, EPIZYME shall identify Pre-Collaboration Existing CELGENE [**] Compounds that EPIZYME has identified as satisfying the hit criteria that
the Parties, acting through the JRC, have mutually agreed on for the [**] Target (the “[**] Hit Criteria”), and such Pre-Collaboration Existing CELGENE [**] Compounds that are so identified by EPIZYME shall each be deemed to be a
“Once Confirmed Hit”. For the avoidance of doubt, at this stage EPIZYME will not yet know, nor shall EPIZYME perform, directly or indirectly, any testing or any other activity to determine, the identity or structures of any of the
Pre-Collaboration Existing CELGENE [**] Compounds; 
 e. Upon identification by EPIZYME of the Once Confirmed Hits described in the
foregoing clause d, CELGENE shall elect which such Once Confirmed Hits to further progress through the evaluation process in clause (f) below and shall notify EPIZYME of such election. If CELGENE elects to further progress such Once Confirmed
Hit through the evaluation process in clause (f), CELGENE will complete resynthesis (including analytical characterization) and send the resynthesized Once Confirmed Hit to EPIZYME for performance of the testing described in clause f below; 

f. EPIZYME may retest the resynthesized Once Confirmed Hits that CELGENE provides, in EPIZYME’s [**] assay (IC50 determination), [**]
assay, and in an assay designed to detect [**]. The resynthesized Once Confirmed Hits that are reconfirmed through such retesting by EPIZYME as satisfying the [**] Hit Criteria established by the JRC for [**] shall each be deemed to be a
“Twice Confirmed Hit”. For the avoidance of doubt, at this stage EPIZYME will not yet know, nor shall EPIZYME perform, directly or indirectly, any testing or any other activity to determine, the identity or structures of any of the
Pre-Collaboration Existing CELGENE [**] Compounds; 
 g. Each Twice Confirmed Hit will (unless CELGENE notifies EPIZYME pursuant to clause
(i) below that CELGENE has elected not to introduce such Twice Confirmed Hit into the Collaboration) be provided by CELGENE to a Third Party chemist (for such [**] evaluation as agreed between CELGENE and EPIZYME through the JRC) and the
information obtained from such [**] evaluation will (unless CELGENE notifies EPIZYME pursuant to clause (i) below that CELGENE has elected not to introduce such Twice Confirmed Hit into the Collaboration) be provided by CELGENE to a Third Party
patent attorney (for such [**] evaluation as agreed between CELGENE and EPIZYME through the JRC) (each such Third Party, a “Third Party External Reviewer” and collectively, the “Third Party External Reviewers”). The
Third Party External Reviewers shall be designated by EPIZYME and reasonably acceptable to CELGENE, and shall not be, and shall not in the past [**] years have been, an employee, consultant, legal advisor, officer, director or stockholder of, and
shall not have any conflict of interest with respect to, either Party; provided that, no Third Party consultant or legal advisor will be so disqualified by virtue of being or having been engaged by EPIZYME to assist with [**] (i.e.,
Third Party consultants and legal advisors who have then been engaged by EPIZYME within the past [**] years to 

  
 2 

 
conduct work on EPIZYME programs or to advise EPIZYME as to the prosecution of EPIZYME’s patent portfolio would be disqualified, but Third Party consultants and legal advisors who have then
been engaged by EPIZYME to assist with [**], whether within the past [**] years or otherwise, would not be disqualified on account of such engagements). All fees and expenses payable to the Third Party External Reviewers shall be borne solely by
Epizyme. CELGENE shall disclose to such Third Party External Reviewers (but not to EPIZYME) the identity and structures of such Twice Confirmed Hits. For clarity, the foregoing evaluation and information exchange shall not commence until after such
time as each of CELGENE and EPIZYME, on the one hand, and each Third Party External Reviewer, on the other hand, enter into such reasonable confidentiality agreements as CELGENE or EPIZYME, as applicable, requires. The Third Party External Reviewers
shall develop a report based on the their evaluation of each Twice Confirmed Hit (such report, the “ER Report” and such information contained therein, the “ER Report Information”). The ER Report shall be submitted
to CELGENE in draft form for CELGENE’S review, comment and redaction of any information regarding Twice Confirmed Hits which CELGENE does not authorize for disclosure to EPIZYME (the “CELGENE Review”). The Third Party External
Reviewers shall comply with any comments, requests, edits or redactions proposed by CELGENE through the CELGENE Review and the Third Party External Reviewers shall not otherwise modify or update the ER Report with additional information regarding
Twice Confirmed Hits, after completion of the CELGENE Review; [**] and the Third Party External Reviewers shall thereafter include in their reports a general description of any effects on the completeness or accuracy of their evaluation conclusions
resulting from their compliance with such CELGENE-required comments, requests, edits or redactions. The process set forth for the CELGENE Review shall repeat until the ER Report is satisfactory to CELGENE. When the ER Report is satisfactory to
CELGENE, CELGENE shall provide the Third Party External Reviewers with written authorization approving disclosure of the ER Report to EPIZYME (the “CELGENE ER Report Approval”). The ER Report shall not be delivered to EPIZYME until
after the Third Party External Reviewers receive the CELGENE ER Report Approval. For clarity, the ER Report shall not list and the ER Report Information shall not contain, the identity or chemical structure of any Twice Confirmed Hit or any
information from which the identity or chemical structure of any Twice Confirmed Hit could reasonably be determined. Other than disclosing the ER Report Information in the form of the ER Report to EPIZYME, the Third Party External Reviewers shall
not and EPIZYME shall not request that the External Reviewers: (i) disclose to EPIZYME or any Person (other than CELGENE), any information of CELGENE or its Affiliates used or generated in connection with the Third Party External Reviewers
evaluation of the Twice Confirmed Hits, or (ii) discuss or provide any analysis or discussion of any information of CELGENE or its Affiliates used or generated in connection with the Third Party External Reviewers evaluation of the Twice
Confirmed Hits. Each Party shall treat the ER Report and the ER Report Information as Confidential Information of the other Party. Distribution of the ER Report shall be reasonably limited within EPIZYME to only those employees who require the ER
Report Information to make or participate in deliberations or decisions with respect to those Twice Confirmed Hits that satisfy or do not satisfy the criteria set forth in clause h below. Distribution of the ER Report shall be reasonably limited
within CELGENE to only those employees who require the ER Report Information to make or participate in deliberations or decisions with respect to those Twice Confirmed Hits for purposes of the Collaboration; 

h. EPIZYME shall notify CELGENE of those Twice Confirmed Hits that satisfy the [**] criteria mutually agreed by the Parties through the JRC,
for further research and development; and 
 i. Upon receipt by CELGENE of notice under clause h above that a Twice Confirmed Hit satisfies
the referenced [**] criteria, the Parties shall negotiate in good faith to execute a transfer agreement substantially in the form of Exhibit B (each, a “CELGENE Provided Compound Transfer Agreement”), which shall provide for the
disclosure by CELGENE to EPIZYME of the identity and chemical structure of such compound after execution of such CELGENE Provided Compound Transfer Agreement; it being understood and agreed that no information or data relating to such CELGENE

  
 3 

 
Provided Compound other than its identity and chemical structure as set forth on the CELGENE Provided Compound Transfer Agreement is required to be disclosed or provided by CELGENE under this
Agreement or the CELGENE Provided Compound Transfer Agreement. Upon execution of the CELGENE Provided Compound Transfer Agreement, such compound shall be (A) deemed a Compound and a CELGENE Provided Compound and (B) available for further
research and Development under the Research Plan and, if applicable, the Development Plan for the applicable Selected Target. 
 For the
avoidance of doubt, (x) if CELGENE notifies EPIZYME, prior to execution of the CELGENE Provided Compound Transfer Agreement by both Parties as set forth in clause i above, that CELGENE elects not to introduce a Once Confirmed Hit or Twice
Confirmed Hit into the Collaboration, the applicable compound shall not be a Compound (except for purposes of Section 7.1) or a CELGENE Provided Compound; (y) EPIZYME shall not be permitted to cross-screen any compound(s) provided under
clause a above against any other Available Targets unless and until such compound(s) become CELGENE Provided Compound(s) as set forth in clause i above; and (z) subject to Section 8.1.3(a), any compound, including Compounds, Controlled by
CELGENE or any of its Affiliates as of the Effective Date or thereafter during the Term other than a Compound that is (I) provided to EPIZYME in accordance with this Amendment or Section 2.2.2(a)(iii), or (II) based upon or derived from a
Compound described in subclause (I) and that is synthesized, identified or discovered during the conduct of the Collaboration in accordance with this Agreement, shall not be subject to the licenses set forth in Article 5. 

4. Miscellaneous. The Parties hereby confirm and agree that, other than as amended hereby, the provisions of the Agreement shall
remain unchanged and in full force and effect and the Agreement remains a binding obligation of the Parties, and that the provisions and terms and conditions of this Amendment shall apply only with respect to the evaluation of Pre-Collaboration
Existing CELGENE [**] Compounds. This Amendment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile signatures and signatures transmitted via
PDF shall be treated as original signatures. Headings used herein are for convenience only and shall not in any way affect the construction of or be taken into consideration in interpreting the Agreement. 

[Remainder of page intentionally left blank] 

  
 4 

 IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their duly
authorized representatives. 
  

									
	EPIZYME, INC.	 		 	CELGENE INTERNATIONAL SÀRL
					
	By:	 	 /s/ Jason Rhodes
	 		 	By:	 	 /s/ Jürg Oehen

					
	Name:	 	Jason Rhodes	 		 	Name:	 	 Jürg Oehen

					
	Title:	 	President and CFO	 		 	Title:	 	 Director

				
	CELGENE CORPORATION	 		 		 	
					
	By:	 	 /s/ Perry Karsen
	 		 		 	
					
	Name:	 	 Perry Karsen
	 		 		 	
					
	Title:	 	 COO
	 		 		 	

  
 5EX-4.1

 Exhibit 4.1 

EXECUTION VERSION 
  

 
  

ANHEUSER-BUSCH INBEV FINANCE INC. 

and 
 ANHEUSER-BUSCH INBEV SA/NV

 and 
 the SUBSIDIARY
GUARANTORS party hereto from time to time 
 and 

THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. 

Trustee 
  

 
 SEVENTH SUPPLEMENTAL INDENTURE 

Dated as of January 27, 2014 
  

 
 To the Indenture, dated as of
January 17, 2013, 
 among Anheuser-Busch InBev Finance Inc., 

Anheuser-Busch InBev NV/SA, the Subsidiary Guarantors party thereto from time to time and 

The Bank of New York Mellon Trust Company, N.A., Trustee 

Floating Rate Notes due 2017 
  

 
  

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	
	ARTICLE I	  
	
	DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION	  
			
	SECTION 1.01	 	 Definitions
	  	 	2	  
	SECTION 1.02	 	 Effect of Headings
	  	 	3	  
	SECTION 1.03	 	 Separability Clause
	  	 	4	  
	SECTION 1.04	 	 Benefits of Instrument
	  	 	4	  
	
	ARTICLE II	  
	
	FLOATING RATE NOTES DUE 2017	  
			
	SECTION 2.01	 	 Creation of Series; Establishment of Form
	  	 	4	  
	SECTION 2.02	 	 Guarantee
	  	 	5	  
	SECTION 2.03	 	 Interest
	  	 	5	  
	SECTION 2.04	 	 Payment of Principal, Interest and Other Amounts
	  	 	7	  
	SECTION 2.05	 	 Optional Tax Redemption
	  	 	7	  
	
	ARTICLE III	  
	
	MISCELLANEOUS PROVISIONS	  
			
	SECTION 3.01	 	 Effectiveness
	  	 	8	  
	SECTION 3.02	 	 Original Issue
	  	 	8	  
	SECTION 3.03	 	 Ratification and Integral Part
	  	 	8	  
	SECTION 3.04	 	 Priority
	  	 	8	  
	SECTION 3.05	 	 Successors and Assigns
	  	 	8	  
	SECTION 3.06	 	 Counterparts
	  	 	8	  
	SECTION 3.07	 	 Guarantee Limitations
	  	 	9	  
	SECTION 3.08	 	 The Trustee
	  	 	9	  
	SECTION 3.09	 	 Governing Law
	  	 	9	  
			
	EXHIBIT A	 		  	 	A-1	  
	EXHIBIT B	 		  	 	B-1	  

  
 - i - 

 SEVENTH SUPPLEMENTAL INDENTURE, dated as of January 27, 2014 (the “Seventh
Supplemental Indenture”), among ANHEUSER-BUSCH INBEV FINANCE INC., a corporation duly organized and existing under the laws of the State of Delaware (the “Company”), ANHEUSER-BUSCH INBEV NV/SA, a société
anonyme duly organized and existing under the laws of the Kingdom of Belgium (the “Parent Guarantor”), ANHEUSER-BUSCH INBEV WORLDWIDE, INC., a corporation duly organized and existing under the laws of the State of Delaware,
BRANDBEV S.À R.L., a société à responsabilité limitée incorporated under the laws of Luxembourg, with registered office at 5, Rue Gabriel Lippmann, L-5365 Münsbach, Luxembourg, registered
with the Luxembourg Register of Commerce and Companies under the number B 80.984 and having a share capital of USD 30,020,720, BRANDBREW S.A., a société anonyme incorporated under the laws of Luxembourg, with its registered
address at 5, rue Gabriel Lippmann, L-5365 Luxembourg and registered with the Luxembourg register of commerce and companies under number B-75696, COBREW NV, a public limited liability company organized and existing under Belgian law, ANHEUSER-BUSCH
COMPANIES, LLC, a limited liability company duly organized and existing under the laws of the State of Delaware, (each, a “Subsidiary Guarantor”, and together with the Parent Guarantor, the “Guarantors”) and The
Bank of New York Mellon Trust Company, N.A., as trustee (the “Trustee”) to the Indenture, dated as of January 17, 2013, among the Company, the Guarantors and the Trustee (the “Indenture”). 

RECITALS OF THE COMPANY AND THE GUARANTORS 

WHEREAS, the Company, the Guarantors and the Trustee are parties to the Indenture, which provides for the issuance from time to time of
unsecured debt securities of the Company; 
 WHEREAS, Section 901(9) of the Indenture permits supplements thereto without the consent
of Holders of Securities to establish the form or terms of Securities of any series as permitted by Sections 201 and 301 of the Indenture; 

WHEREAS, as contemplated by Section 301 of the Indenture, the Company intends to issue a new series of Securities to be known as the
Company’s “Floating Rate Notes due 2017” (the “Notes”) under the Indenture; 
 WHEREAS, the Company and the
Guarantors have taken all necessary corporate action to authorize the execution and delivery of this Seventh Supplemental Indenture; 
 NOW,
THEREFORE, THIS SEVENTH SUPPLEMENTAL INDENTURE WITNESSETH: 
 For and in consideration of the premises and the other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the Company, the Guarantors and the Trustee mutually agree as follows: 

  
 - 1 - 

 ARTICLE I 

DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 

SECTION 1.01 Definitions. 

Except as otherwise expressly provided or unless the context otherwise requires, all terms used in this Seventh Supplemental Indenture which
are defined in the Indenture shall have the meanings ascribed to them by the Indenture. The following terms used in this Seventh Supplemental Indenture have the following respective meanings: 

“3-Month LIBOR” has the meaning specified in Section 2.03. 

“Business Day” means a day on which commercial banks and exchange markets are open, or not authorized to
close, in the City of New York, London and Brussels. 
 “Business Day Convention” means that if any Interest
Payment Date (other than the Stated Maturity or a date fixed for redemption or payment in connection with an acceleration of the Notes) falls on a day that is not a Business Day, that Interest Payment Date will be postponed to the next succeeding
Business Day unless that Business Day is in the next succeeding calendar month, in which case the Interest Payment Date will be the immediately preceding Business Day. 

“Calculation Agent” means The Bank of New York Mellon Trust Company, N.A. 

“Change in Tax Law” has the meaning set forth in Section 2.05(a). 

“Company” has the meaning set forth in the first paragraph of this Seventh Supplemental Indenture. 

“Date of the Prospectus Supplement” means January 22, 2014 which is the date of the final Prospectus
Supplement prepared in connection with the issuance of the Notes and filed with the Securities and Exchange Commission. 

“Depositary” means The Depository Trust Company, or any successor thereto. 

“Global Security” has the meaning set forth in Section 2.01(d). 

“Guarantors” has the meaning set forth in the first paragraph of this Seventh Supplemental Indenture. 

  
 - 2 - 

 “Indenture” has the meaning set forth in the first paragraph of
this Seventh Supplemental Indenture. 
 “Interest Determination Date” means, for each particular Interest
Reset Date (as defined below), the second London Business Day (as defined below) preceding such Interest Reset Date. 

“Interest Payment Date” has the meaning specified in Section 2.03. 

“Interest Period” means the period beginning on, and including, an Interest Payment Date and ending on, but
not including, the following Interest Payment Date; provided that the first Interest Period will begin on January 27, 2014, and will end on, but not include, the first Interest Payment Date. 

“Interest Reset Date” means, for each Interest Period other than the first Interest Period, the first day of
such Interest Period, subject to the Business Day Convention. 
 “London Business Day” means any week day on
which banking or trust institutions in London are not authorized generally or obligated by law, regulation or executive order to close. 

“Notes” has the meaning set forth in the Recitals. 

“Parent Guarantor” has the meaning set forth in the first paragraph of this Seventh Supplemental Indenture.

 “Regular Record Date” means the fifteenth calendar day immediately preceding the applicable Interest
Payment Date, whether or not such day is a Business Day. 
 “Seventh Supplemental Indenture” has the meaning
set forth in the Recitals. 
 “Spread” has the meaning specified in Section 2.03. 

“Stated Maturity” has the meaning specified in Section 2.01(f). 

“Trustee” has the meaning set forth in the first paragraph of this Seventh Supplemental Indenture. 

SECTION 1.02 Effect of Headings. 

The Article and Section headings herein are for convenience only and shall not affect the construction hereof. 

  
 - 3 - 

 SECTION 1.03 Separability Clause. 

In case any provision in this Seventh Supplemental Indenture shall be invalid, illegal or unenforceable, the validity, legality and
enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 
 SECTION 1.04 Benefits of
Instrument. 
 Nothing in this Seventh Supplemental Indenture, express or implied, shall give to any Person, other than the parties
hereto and their successors hereunder and the Holders, any benefit or any legal or equitable right, remedy or claim under this Seventh Supplemental Indenture or the Indenture. 

ARTICLE II 
 FLOATING
RATE NOTES DUE 2017 
 SECTION 2.01 Creation of Series; Establishment of Form. 

(a) There is hereby established a new series of Securities under the Indenture entitled “Floating Rate Notes due 2017”. 

(b) The form of the Notes, including the form of the certificate of authentication, is attached hereto as Exhibit A. 

(c) The Company shall issue the Notes in an aggregate principal amount of USD 300,000,000. The Company may from time to time, without the
consent of the Holders of the Notes, issue additional Notes in accordance with Sections 301 and 901 of the Indenture. Any such additional Notes subsequently issued shall rank equally and ratably with the Notes in all respects (except for the
payment of interest accruing prior to the issue date of such further Notes or except for the first payment of interest following the issue date of such further Notes), so that such further Notes shall be consolidated and form a single series with
the Notes and shall have the same terms as to status, redemption or otherwise as the Notes. 
 (d) The Notes shall be issued initially in
the form of one or more permanent global securities, without coupons, registered in the name of the Depositary or a nominee of the Depositary (each, a “Global Security”) and deposited with the Trustee, as custodian for the
Depositary. Any proposed transfer of an interest in the Notes shall consist of a transfer within a Global Security and shall be effected through the book-entry system maintained by the Depositary. 

(e) The Notes shall not have a sinking fund. 

  
 - 4 - 

 (f) The stated maturity of the principal of the Notes shall be January 27, 2017 (the
“Stated Maturity”). 
 (g) The outstanding principal amount of the Notes shall accrue interest at a rate per year equal to
3-Month LIBOR, reset quarterly, plus the Spread, as provided in Section 2.03. 
 (h) The Notes shall be issued in denominations of USD
1,000 in principal amount and integral multiples of USD 1,000 in excess thereof. 
 (i) The Notes shall be subject to both Defeasance and
Covenant Defeasance in accordance with the Indenture. 
 (j) The Notes shall be senior unsecured obligations of the Company and will rank
equally with all other existing and future unsecured and unsubordinated debt obligations of the Company. 
 SECTION 2.02 Guarantee.
Subject to the terms and applicable limitations set forth in the Indenture and the form of Notes, the Notes shall be jointly and severally, irrevocably, fully and unconditionally guaranteed by the Guarantors as to all payments due on the Notes
whether at their Stated Maturity, by acceleration, redemption, repayment or otherwise in accordance with the terms of such Guarantees and the Indenture. In the case of the failure of the Company to pay punctually any principal of or interest on the
Notes, the Guarantors shall cause any such payment to be made as it becomes due and payable, whether at maturity, upon acceleration, redemption, repayment or otherwise. The Guarantees shall be unsecured and unsubordinated indebtedness of the
Guarantors and rank equally with other unsecured and unsubordinated indebtedness of the Guarantors that is currently outstanding or that they may issue in the future. 

SECTION 2.03 Interest. The Notes shall bear interest at a floating rate per year equal to the 3-Month U.S. dollar London Interbank
Offered Rate (“3-Month LIBOR”), reset quarterly, plus 0.19% (the “Spread”), as described below. Interest will accrue from January 27, 2014 or from the most recent Interest Payment Date to which interest has
been paid or duly provided for, as the case may be. Interest is payable quarterly, in arrears, on January 27, April 27, July 27 and October 27 of each year, subject to the Business Day Convention (each, an
“Interest Payment Date”), commencing on April 27, 2014 to the Person in whose name the Notes were registered at the close of business on the Regular Record Date immediately preceding the applicable Interest Payment Date,
whether or not such day is a Business Day, until the principal thereof is paid or made available for payment. 
 If the date of maturity of
principal of the Notes or the date fixed for redemption or payment in connection with an acceleration of any Note is not a Business Day, then payment of interest or principal need not be made on such date, but may be made on the next succeeding
Business Day with the same force and effect as if made on the date of maturity or the date fixed for redemption or payment in connection with acceleration, and no interest shall accrue as a result of the delayed payment. 

  
 - 5 - 

 The interest rate on the Notes for the first Interest Period will be 3-Month LIBOR, as determined
on January 23, 2014 (treating January 23, 2014 as if it were an Interest Determination Date and January 27, 2014 as the related Interest Reset Date), plus the Spread. Thereafter, the interest rate on the Notes for any Interest Period
will be 3-Month LIBOR, as determined on the applicable Interest Determination Date, plus the Spread. The interest rate on the Notes will be reset quarterly on each Interest Reset Date. For each Interest Period, interest on the Notes will be
calculated on the basis of the actual number of days in the Interest Period divided by 360. 
 The Calculation Agent will determine 3-Month
LIBOR in accordance with the following provisions: With respect to any Interest Determination Date, 3-Month LIBOR will be the rate for deposits in U.S. dollars having a maturity of three months commencing on the related Interest Reset Date that
appears on the designated LIBOR page as of 11:00 a.m., London time, on that Interest Determination Date. If no rate appears, 3-Month LIBOR, in respect of that Interest Determination Date, will be determined as follows: the Calculation Agent will
request the principal London offices of each of four major reference banks in the London interbank market, as selected and identified by the Company, to provide the Calculation Agent with its offered quotation for deposits in U.S. dollars for the
period of three months, commencing on the Interest Reset Date, to prime banks in the London interbank market at approximately 11:00 a.m., London time, on that Interest Determination Date and in a principal amount that is representative for a single
transaction in U.S. dollars in that market at that time. If at least two quotations are provided, then 3-Month LIBOR on that Interest Determination Date will be the arithmetic mean of those quotations. If fewer than two quotations are provided, then
3-Month LIBOR on the Interest Determination Date will be the arithmetic mean of the rates quoted at approximately 11:00 a.m., New York City time, on the Interest Determination Date by three major banks in The City of New York as selected and
identified by the Company for loans in U.S. dollars to leading European banks, having a three-month maturity and in a principal amount that is representative for a single transaction in U.S. dollars in that market at that time; provided, however,
that if the banks selected and identified by the Company are not providing quotations in the manner described by this sentence, 3-Month LIBOR determined as of that Interest Determination Date will be 3-Month LIBOR in effect on that Interest
Determination Date. The designated LIBOR page is the Reuters screen “LIBOR01”, or any successor service for the purpose of displaying the London interbank rates of major banks for U.S. dollars. The Reuters screen “LIBOR01” is the
display designated as the Reuters screen “LIBOR01”, or such other page as may replace the Reuters screen “LIBOR01” on that service or such other service or services as may be denominated for the purpose of displaying London
interbank offered rates for U.S. dollar deposits by the British Bankers’ Association (the “BBA”), its successor, such as ICE Benchmark Administration Limited or such other entity assuming the responsibility of the BBA or its
successor in calculating the London Inter-Bank Offered Rate in the event the BBA or its successor no longer does so. 

  
 - 6 - 

 All calculations made by the Calculation Agent for the purposes of calculating the interest rate
on the Notes shall be conclusive and binding on the Holders, the Company and the Trustee, absent manifest error. 
 SECTION 2.04 Payment
of Principal, Interest and Other Amounts. Payments of principal of and interest on the Notes shall be made in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts
and such payments on Notes represented by a Global Security shall be made through one or more Paying Agents appointed under the Indenture to the Depositary or its nominee, as the Holder of the Global Security. Initially, the Paying Agent and
Registrar for the Notes will be The Bank of New York Mellon Trust Company, N.A., in St. Louis, Missouri. The Company may change the Paying Agent or Registrar without prior notice to the Holders of the Notes, and in such an event the Company may act
as Paying Agent or Registrar. Payments of principal of and interest on the Notes represented by a Global Security shall be made by wire transfer of immediately available funds; provided, however, that in the case of payments of
principal, such Global Security is first surrendered to the Paying Agent. 
 SECTION 2.05 Optional Tax Redemption. 

(a) The Company may, at the Company’s or the Parent Guarantor’s option, redeem the Notes in whole but not in part, upon not less
than thirty (30) nor more than sixty (60) days’ prior notice, at a redemption price equal to 100% of the principal amount of the Notes then outstanding plus accrued and unpaid interest on the principal amount being redeemed (and all
Additional Amounts, if any) to (but excluding) the Redemption Date, if (i) as a result of any change in, or amendment to, the laws, treaties, regulations or rulings of a jurisdiction in which the Company or any Guarantor is incorporated,
organized, or otherwise tax resident or any political subdivision or any authority thereof or therein having power to tax, or in the interpretation, application or administration of any such laws, treaties, regulations or rulings (including a
holding, judgment or order by a court of competent jurisdiction) which becomes effective on or after the Date of the Prospectus Supplement (any such change or amendment, a “Change in Tax Law”), the Company or, if a payment were then
due under a Guarantee, the relevant Guarantor, would be required to pay Additional Amounts and (ii) such obligation cannot be avoided by the Company or the relevant Guarantor taking reasonable measures available to it; provided, however, that
the Notes may not be redeemed to the extent such Additional Amounts arise solely as a result of the Company assigning its obligations under the Notes to a Substitute Company (as defined in Section 801 of the Indenture), unless such assignment
to a Substitute Company is undertaken as part of a plan of merger by the Parent Guarantor. 

  
 - 7 - 

 (b) Prior to the mailing of any notice of redemption pursuant to this Section 2.05, the
Company or the relevant Guarantor will deliver to the Trustee an opinion of independent tax counsel of recognized standing to the effect that the Company or the relevant Guarantor is or would be obligated to pay such Additional Amounts as a result
of such Change in Tax Law. 
 (c) No notice of redemption pursuant to this Section 2.05 may be given earlier than ninety (90) days
prior to the earliest date on which the Company or the relevant Guarantor would be obligated to pay Additional Amounts if a payment in respect of the Notes were then due. 

ARTICLE III 

MISCELLANEOUS PROVISIONS 

SECTION 3.01 Effectiveness. This Seventh Supplemental Indenture will become effective upon its execution and delivery. 

SECTION 3.02 Original Issue. The Notes may, upon execution of this Seventh Supplemental Indenture, be executed by the Company and
delivered by the Company and the Parent Guarantor to the Trustee for authentication, and the Trustee shall, upon Company order, authenticate and deliver such Notes as in such Company order provided. 

SECTION 3.03 Ratification and Integral Part. The Indenture as supplemented by this Seventh Supplemental Indenture, is in all respects
ratified and confirmed, and this Seventh Supplemental Indenture will be deemed an integral part of the Indenture in the manner and to the extent herein and therein provided. 

SECTION 3.04 Priority. This Seventh Supplemental Indenture shall be deemed part of the Indenture in the manner and to the extent herein
and therein provided. The provisions of this Seventh Supplemental Indenture shall, subject to the terms hereof, supersede the provisions of the Indenture to the extent the Indenture is inconsistent herewith. 

SECTION 3.05 Successors and Assigns. All covenants and agreements in the Indenture, as supplemented and amended by this Seventh
Supplemental Indenture, by the Company and the Guarantors will bind their respective successors and assigns, whether so expressed or not. 

SECTION 3.06 Counterparts. This Seventh Supplemental Indenture may be executed in any number of counterparts, each of which so executed
shall be deemed to be an original, but all such counterparts shall together constitute but one and the same instrument. 

  
 - 8 - 

 SECTION 3.07 Guarantee Limitations. The limitations applicable to the Guarantees, as set
forth in Section 209 of the Indenture, will apply to the Guarantees issued hereunder, provided that any further limitations, or any amendments or modifications to such Guarantees or limitations thereon, shall be set forth in an additional
supplemental indenture, in each case in accordance with the Indenture. 
 SECTION 3.08 The Trustee. The Trustee shall not be
responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Seventh Supplemental Indenture or for or in respect of the recitals contained herein, all of which are made solely by the Company and the Guarantors. 

SECTION 3.09 Governing Law. This Seventh Supplemental Indenture and the Notes and Guarantees will be governed by and construed in
accordance with the laws of the State of New York. 

  
 - 9 - 

 IN WITNESS WHEREOF, the parties hereto have caused this Seventh Supplemental Indenture to be duly
executed, all as of the day and year first above written. 
  

					
	 ANHEUSER-BUSCH INBEV FINANCE INC.

as Company

		
	By:	 	 /s/ Matthew Amer

		 	Name:	 	Matthew Amer
		 	Title:	 	Authorized Officer
	
	 ANHEUSER-BUSCH INBEV NV/SA

as Parent Guarantor

		
	By:	 	 /s/ Benoit Loore

		 	Name:	 	Benoit Loore
		 	Title:	 	Authorized Officer
		
	By:	 	 /s/ Patricia Frizo

		 	Name:	 	Patricia Frizo
		 	Title:	 	Authorized Officer
	
	 THE BANK OF NEW YORK MELLON
TRUST COMPANY, N.A., 
 as Trustee

		
	By:	 	 /s/ Teresa Petta

		 	Name:	 	Teresa Petta
		 	Title:	 	Vice President

 
					
	 ANHEUSER-BUSCH INBEV WORLDWIDE INC.

As Subsidiary Guarantor

		
	By:	 	 /s/ Matthew Amer

		 	Name:	 	Matthew Amer
		 	Title:	 	Authorized Officer
	
	 ANHEUSER-BUSCH COMPANIES, LLC

As Subsidiary Guarantor

		
	By:	 	 /s/ Matthew Amer

		 	Name:	 	Matthew Amer
		 	Title:	 	Authorized Officer
	
	 COBREW NV

as Subsidiary Guarantor

		
	By:	 	 /s/ Benoit Loore

		 	Name:	 	Benoit Loore
		 	Title:	 	Authorized Officer
		
	By:	 	 /s/ Patricia Frizo

		 	Name:	 	Patricia Frizo
		 	Title:	 	Authorized Officer
	
	 BRANDBREW S.A.

as Subsidiary Guarantor

		
	By:	 	 /s/ Benoit Loore

		 	Name:	 	Benoit Loore
		 	Title:	 	Authorized Officer

 
					
	 BRANDBEV S. À R.L.

as Subsidiary Guarantor

		
	By:	 	 /s/ Benoit Loore

		 	Name:	 	Benoit Loore
		 	Title:	 	Authorized Officer

 Exhibit A 

FORM OF NOTES 
 FACE OF
SECURITY 
 THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF
A DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY OR A
NOMINEE THEREOF, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. 
 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED
REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO ANHEUSER-BUSCH INBEV FINANCE INC. OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF
CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR
OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 

  
 A-1 

 Exhibit A 
  

 Anheuser-Busch InBev Finance Inc. 

Floating Rate Note due 2017 

Payment of Principal 
 and Interest
Irrevocably, Fully and Unconditionally Guaranteed by 
 Anheuser-Busch InBev NV/SA,
Anheuser-Busch InBev Worldwide, Inc., Brandbev 
 S.à r.l., BrandBrew S.A.,
Cobrew NV and Anheuser-Busch Companies, LLC 
  

			
	No.     	  	USD                  
		
	CUSIP No. 03524B AD8	  	ISIN: US03524BAD82        

 Anheuser-Busch InBev Finance Inc., a corporation duly organized and existing under the laws of the State of
Delaware (herein called the “Company”, which term includes any successor Person under the Indenture hereinafter referred to), for value received, hereby promises to pay to Cede & Co., or its registered assigns, on
January 27, 2017 (the “Maturity Date”), the principal sum of USD         , and to pay interest thereon from January 27, 2014 or from the most recent Interest Payment Date to which
interest has been paid or duly provided for, quarterly, in arrears, on January 27, April 27, July 27 and October 27, subject to the Business Day Convention, in each year, commencing on April 27, 2014, at a floating
rate equal to 3-Month LIBOR, reset quarterly, plus 0.19%, per annum, as described below, until the principal hereof is paid or made available for payment. 

The interest rate on the Notes for the first Interest Period will be 3-Month LIBOR, as determined on January 23, 2014 (treating
January 23, 2014 as if it were an Interest Determination Date and January 27, 2014 as the related Interest Reset Date), plus the Spread. Thereafter, the interest rate on the Notes for any Interest Period will be 3-Month LIBOR, as
determined on the applicable Interest Determination Date, plus the Spread. The interest rate on the Notes will be reset quarterly on each Interest Reset Date. For each Interest Period, interest on the Notes will be calculated on the basis of the
actual number of days in the Interest Period divided by 360. 
 The Calculation Agent will determine 3-Month LIBOR in accordance with the
following provisions: With respect to any Interest Determination Date, 3-Month LIBOR will be the rate for deposits in U.S. dollars having a maturity of three months commencing on the related Interest Reset Date that appears on the designated LIBOR
page as of 11:00 a.m., London time, on that Interest Determination Date. If no rate appears, 3-Month LIBOR, in respect of that Interest Determination Date, will be determined as follows: the Calculation Agent will request the principal London
offices of each of four major reference banks in the London interbank market, as selected and identified by the Company, to provide the Calculation Agent with its offered quotation for deposits in U.S. dollars for the period of three months,
commencing on the Interest Reset Date, to prime banks in the London interbank market at approximately 11:00 a.m., London time, on that Interest Determination Date and in a principal amount that is 

  
 A-2 

 Exhibit A 
  

 
representative for a single transaction in U.S. dollars in that market at that time. If at least two quotations are provided, then 3-Month LIBOR on
that Interest Determination Date will be the arithmetic mean of those quotations. If fewer than two quotations are provided, then 3-Month LIBOR on the Interest Determination Date will be the arithmetic mean of the rates quoted at approximately 11:00
a.m., New York City time, on the Interest Determination Date by three major banks in The City of New York as selected and identified by the Company for loans in U.S. dollars to leading European banks, having a three-month maturity and in a principal
amount that is representative for a single transaction in U.S. dollars in that market at that time; provided, however, that if the banks selected and identified by the Company are not providing quotations in the manner described by this sentence,
3-Month LIBOR determined as of that Interest Determination Date will be 3-Month LIBOR in effect on that Interest Determination Date. The designated LIBOR page is the Reuters screen “LIBOR01”, or any successor service for the purpose of
displaying the London interbank rates of major banks for U.S. dollars. The Reuters screen “LIBOR01” is the display designated as the Reuters screen “LIBOR01”, or such other page as may replace the Reuters screen
“LIBOR01” on that service or such other service or services as may be denominated for the purpose of displaying London interbank offered rates for U.S. dollar deposits by the British Bankers’ Association (the “BBA”), its
successor, such as ICE Benchmark Administration Limited or such other entity assuming the responsibility of the BBA or its successor in calculating the London Inter-Bank Offered Rate in the event the BBA or its successor no longer does so. 

All calculations made by the Calculation Agent for the purposes of calculating the interest rate on the Notes shall be conclusive and binding
on the Holders, the Company and the Trustee, absent manifest error. 
 The interest so payable, and punctually paid or duly provided for on
any Interest Payment Date will, as provided in the Indenture, be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on Regular Record Date for such interest, which shall be
the fifteenth calendar day immediately preceding the applicable Interest Payment Date, whether or not such day is a Business Day. Any such interest not so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such
Regular Record Date and may either be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on a Special Record Date for the payment of such Defaulted Interest to be fixed by
the Trustee, notice whereof shall be given to Holders of Securities of this series not less than 10 days prior to such Special Record Date, or be paid at any time in any other lawful manner not inconsistent with the requirements of any securities
exchange on which the Securities of this series may be listed, and upon such notice as may be required by such exchange, all as more fully provided in the Indenture. 

Subject to the terms of the Indenture, this Security is fully and unconditionally guaranteed as to all payments due hereon whether at the
Stated Maturity, by acceleration, redemption, repayment or otherwise in accordance with the terms of the Guarantees and the Indenture. 

  
 A-3 

 Exhibit A 
  

 Payments of principal of and interest on the Notes shall be made in such coin or currency of
the United States of America as at the time of payment is legal tender for payment of public and private debts and such payments on Notes represented by a Global Security shall be made through one or more Paying Agents appointed under the Indenture
to the Depositary or its nominee, as the Holder of this Security. Initially, the Paying Agent and Registrar for the Securities will be The Bank of New York Mellon Trust Company, N.A., St. Louis, Missouri. The Company may change the Paying Agent or
Registrar without prior notice to the Holders, and in such an event the Company may act as Paying Agent or Registrar. Payments of principal of and interest on the Securities represented by this Security shall be made by wire transfer of immediately
available funds; provided, however, that in the case of payments of principal, such Global Security is first surrendered to the Paying Agent. 

Notwithstanding any provision of this Security or the Indenture, the Company may make any and all payments of principal of and interest on
this Security pursuant to the applicable procedures of the Depositary for this Security as permitted in the Indenture. 
 Reference is
hereby made to the further provisions of this Security set forth on the reverse hereof, which further provisions shall for all purposes have the same effect as if set forth at this place. 

Unless the certificate of authentication hereon has been executed by the Trustee referred to on the reverse hereof by manual signature, this
Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 

  
 A-4 

 Exhibit A 
  

 IN WITNESS WHEREOF, the Company has caused this
instrument to be duly executed. 
 Dated: 
  

					
	ANHEUSER-BUSCH INBEV FINANCE INC.
		
	By	 	  

		 	Name:	 	
		 	Title:	 	Authorized Officer

  

	
	Attest:
	
	  

 CERTIFICATE OF AUTHENTICATION 

This Security is one of the Securities of the series designated herein and referred to in the within-mentioned Indenture. 

 

			
	THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee
		
	By	 	  

		 	Authorized Signatory

  
 A-5 

 Exhibit A 
  

 REVERSE OF SECURITY 
  

	 	1.	Securities and Indenture 

 This Security is one of a duly authorized issue of securities
of the Company (payable in U.S. dollars) (herein called the “Securities”), issued and to be issued in one or more series under an Indenture, dated as of January 17, 2013 (the “Base Indenture”), as supplemented
by the Seventh Supplemental Indenture, dated as of January 27, 2014 (the “Seventh Supplemental Indenture” and together with the Base Indenture, the “Indenture”), in each case among the Company, Anheuser-Busch
InBev NV/SA, as Parent Guarantor, the Subsidiary Guarantors party thereto from time to time and The Bank of New York Mellon Trust Company, N.A., as Trustee (herein called the “Trustee”, which term includes any successor trustee
under the Base Indenture), and reference is hereby made to the Indenture for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the Guarantors, the Trustee and the Holders of the Securities
and of the terms upon which the Securities are, and are to be, authenticated and delivered. 
  

	 	2.	Series and Denomination 

 This Security is one of the series designated on the face
hereof, initially limited to an aggregate principal amount of USD 300,000,000, except as provided in the Indenture. References herein to “this series” mean the series of securities designated on the face hereof. Except as provided in the
preceding paragraph, references herein to the “Securities” means (unless the context otherwise requires) the Securities of this series and includes any other securities issued, as provided in the Indenture and forming a single
series with the Securities of this series. 
 The Securities are issuable only in registered form without coupons in denominations of USD
1,000 in principal amount and integral multiples of USD 1,000 in excess thereof. 
  

	 	3.	Optional Tax Redemption 

 The Company may, at the Company’s or the Parent
Guarantor’s option, redeem the Securities of this series in whole, but not in part, upon not less than thirty (30) nor more than sixty (60) days’ prior notice, at a redemption price equal to 100% of the principal amount of the
Securities of this series then outstanding plus accrued and unpaid interest on the principal amount being redeemed (and all Additional Amounts, if any) to (but excluding) the Redemption Date, if (i) as a result of any change in, or amendment
to, the laws, treaties, regulations or rulings of a jurisdiction in which the Company or any Guarantor is incorporated, organized, or otherwise tax resident or any political subdivision or any authority thereof or therein having power to tax, or in
the interpretation, application or administration of any such laws, treaties, regulations or rulings (including a holding, judgment or order by a court of competent jurisdiction) which becomes effective on or after the Date of the Prospectus
Supplement (any such 

  
 A-6 

 Exhibit A 
  

 
change or amendment, a “Change in Tax Law”), the Company or, if a payment were then due under a Guarantee, the relevant Guarantor, would be required to pay Additional Amounts and
(ii) such obligation cannot be avoided by the Company or the relevant Guarantor taking reasonable measures available to it; provided, however, that the Securities of this series may not be redeemed to the extent such Additional Amounts arise
solely as a result of the Company assigning its obligations under the Securities of this series to a Substitute Company, unless such assignment to a Substitute Company is undertaken as part of a plan of merger by the Parent Guarantor. 

Prior to the mailing of any notice of redemption pursuant to this Section, the Company or the relevant Guarantor will deliver to the Trustee
an opinion of independent tax counsel of recognized standing to the effect that the Company or the relevant Guarantor is or would be obligated to pay such Additional Amounts as a result of such Change in Tax Law. 

No notice of redemption pursuant to this Section may be given earlier that ninety (90) days prior to the earliest date on which the
Company or the relevant Guarantor would be obligated to pay Additional Amounts if a payment in respect of the Securities were then due. 
  

	 	4.	Additional Amounts 

 In the event that any Guarantor becomes obligated to make payments
in respect of the Securities of this series, such Guarantor will make all payments in respect of the Securities of this series without withholding or deduction for or on account of any present or future taxes or duties of whatever nature imposed or
levied by way of withholding or deduction at source by or on behalf of any jurisdiction in which such Guarantor is incorporated, organized, or otherwise tax resident or any political subdivision or any authority thereof or therein having power to
tax (the “Relevant Taxing Jurisdiction”) unless such withholding or deduction is required by law. In such event, such Guarantor will pay to the Holders of the Securities of this series such additional amounts (the
“Additional Amounts”) as shall be necessary in order that the net amounts received by the Holders, after such withholding or deduction, shall equal the respective amounts of principal and interest which would otherwise have been
receivable in the absence of such withholding or deduction; except that no such Additional Amounts shall be payable on account of any taxes or duties which: 

(a) are payable by any person acting as custodian bank or collecting agent on behalf of such Holder, or otherwise in any manner
which does not constitute a deduction or withholding by such Guarantor from payment of principal or interest made by it, or 

(b) are payable by reason of such Holder or beneficial owner having, or having had, some personal or business connection with
such Relevant Taxing Jurisdiction and not merely by reason of the fact that payments in respect of the Securities of this series or the Guarantees thereof are, or for purposes of taxation are deemed to be, derived from sources in, or are secured in,
the Relevant Taxing Jurisdiction, or 

  
 A-7 

 Exhibit A 
  

 (c) are imposed or withheld by reason of the failure of such Holder or
beneficial owner to provide certification, information, documents or other evidence concerning the nationality, residence, or identity of the Holder and beneficial owner or to make any valid or timely declaration or similar claim or satisfy any
other reporting requirements relating to such matters, whether required or imposed by statute, treaty, regulation or administrative practice, as a precondition to exemption from, or a reduction in the rate of withholding or deduction of such taxes,
or 
 (d) consist of any estate, inheritance, gift, sales, excise, transfer, personal property or similar taxes, or 

(e) are imposed on or with respect to any payment by the applicable Guarantor to the registered Holder of this Security if such
Holder is a fiduciary or partnership or any person other than the sole beneficial owner of such payment to the extent that taxes would not have been imposed on such payment had such registered Holder been the sole beneficial owner of this Security,
or 
 (f) are deducted or withheld pursuant to (i) any European Union directive or regulation concerning the taxation of
interest income, or (ii) any international treaty or understanding relating to such taxation and to which the Relevant Taxing Jurisdiction or the European Union is a party, or (iii) any provision of law implementing, or complying with, or
introduced to conform with, such directive, regulation, treaty or understanding, or 
 (g) are payable by reason of a change
in law or practice that becomes effective more than 30 days after the relevant payment of principal or interest becomes due, or is duly provided for and written notice thereof is provided to the Holders, whichever occurs later, or 

(h) are payable because this Security was presented to a particular paying agent for payment if this Security could have been
presented to another paying agent without any such withholding or deduction, or 
 (i) are payable for any combination of
(a) through (h) above. 
 References to principal or interest in respect of the Securities of this series shall be deemed to
include any Additional Amounts which may be payable as set forth in the Indenture. 
 The covenant regarding Additional Amounts shall not
apply to any Guarantor at any time when such Guarantor is incorporated in a jurisdiction in the United States, and will apply to the Company any time it is incorporated in a jurisdiction outside of the United States. 

  
 A-8 

 Exhibit A 
  

 In addition, any amounts to be paid by the Company or any Guarantor on the Securities of this
series will be paid net of any deduction or withholding imposed or required pursuant to Sections 1471 through 1474 of the U.S. Internal Revenue Code of 1986, as amended, any current or future regulations or official interpretations thereof, any
agreement entered into pursuant to Section 1471(b) of the U.S. Internal Revenue Code of 1986, as amended, or any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement entered into in connection
with the implementation of such Sections of the Code (“FATCA Withholding”). Neither any Guarantor nor the Company will be required to pay Additional Amounts on account of any FATCA Withholding. 

 

	 	5.	Transfer and Exchange 

 As provided in the Indenture and subject to certain limitations
therein set forth, the transfer of this Security is registrable in the Security Register, upon surrender of this Security for registration of transfer at the office or agency of the Company in any place where the principal of and interest on this
Security are payable, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or his attorney duly authorized in writing, and thereupon
one or more new Securities of this series and of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees. 

As provided in the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like
aggregate principal amount of Securities of this series and of like tenor of a different authorized denomination, as requested by the Holder surrendering the same. 

No service charge shall be made for any such registration of transfer or exchange, but the Company may require payment of a sum sufficient to
cover any tax or other governmental charge payable in connection therewith. 
 Prior to due presentment of this Security for registration of
transfer, the Company, the Guarantors, the Trustee and any agent of the Company, the Guarantors or the Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be
overdue, and neither the Company, the Guarantors, the Trustee nor any such agent shall be affected by notice to the contrary. 
  

	 	6.	Limitation on Suits 

 As provided in and subject to the provisions of the Indenture, the
Holder of this Security shall not have the right to institute any proceeding with respect to the Indenture or for the appointment of a receiver or trustee or for any other remedy thereunder, unless 

  
 A-9 

 Exhibit A 
  

 
such Holder shall have previously given the Trustee written notice of a continuing Event of Default with respect to the Securities of this series, the Holders of not less than 25% in principal
amount of the Securities of this series at the time Outstanding shall have made written request to the Trustee to institute proceedings in respect of such Event of Default as Trustee and offered the Trustee indemnity and/or security, and the Trustee
shall not have received from the Holders of a majority in principal amount of Securities of this series at the time Outstanding a direction inconsistent with such request, and shall have failed to institute any such proceeding, for 60 days after
receipt of such notice, request and offer of indemnity and/or security. The foregoing shall not apply to any suit instituted by the Holder of this Security for the enforcement of any payment of principal hereof or interest hereon on or after the
respective due dates expressed herein. 
 No reference herein to the Indenture and no provision of this Security or of the Indenture shall
alter or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of and interest on this Security at the times, place and rate, and in the coin or currency, herein prescribed. 

 

	 	7.	Amendment, Modification and Waiver 

 The Indenture permits, with certain exceptions as
therein provided, the amendment thereof and the modification of the rights and obligations of the Company or the Guarantors and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company
and the Trustee with the consent of the Holders of a majority in principal amount of the Securities at the time Outstanding (irrespective of series) that are to be affected. The Indenture also contains provisions permitting the Holders of specified
percentages in principal amount of the Securities of each series at the time Outstanding, on behalf of the Holders of all Securities of such series, to waive compliance by the Company and the Guarantors with certain provisions of the Indenture and
certain past defaults under the Indenture and their consequences. Any such consent or waiver by the Holder of this Security shall be conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon
the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Security. 
  

	 	8.	Defeasance 

 The Indenture contains provisions for defeasance at any time of certain
restrictive covenants and Events of Default with respect to this Security upon compliance with certain conditions set forth in the Indenture. 
  

	 	9.	Governing Law 

 This Security shall be governed by and construed in accordance with the
laws of the State of New York. 

  
 A-10 

 Exhibit A 
  

	 	10.	Defined Terms 

 All terms used in this Security which are defined in the Base Indenture
or the Seventh Supplemental Indenture, shall have the meanings assigned to them in the Base Indenture or the Seventh Supplemental Indenture. 

  
 A-11 

 Exhibit B 

FORM OF GUARANTEE 
 For
value received, the undersigned (herein called the “Guarantors”, and each, a “Guarantor” which terms include any successor Person or Persons under the Indenture referred to in the Security upon which this Guarantee is endorsed),
hereby jointly and severally, irrevocably, fully and unconditionally guarantee to the Trustee and to each Holder of this Security, which has been authenticated and delivered by the Trustee, the due and punctual payment of the principal of (including
any amount in respect of original issue discount), and any premium and interest (together with any Additional Amounts payable pursuant to the terms of this Security), on this Security and the due and punctual payment of the sinking fund payments, if
any, and analogous obligations, if any, provided for pursuant to the terms of this Security, when and as the same shall become due and payable, whether at Stated Maturity or upon redemption or upon declaration of acceleration or otherwise according
to the terms of this Security and of the Indenture. In case of default by the Company in the payment of any such principal (including any amount in respect of original issue discount), interest (together with any Additional Amounts payable pursuant
to the terms of this Security), sinking fund payment, or analogous obligation, each Guarantor agrees duly and punctually to pay the same. Each Guarantor hereby agrees that its obligations hereunder shall rank pari passu with all other
unsecured and unsubordinated obligations of such Guarantor, shall be as principal and not merely as surety, and shall be absolute and unconditional irrespective of any extension of the time for payment of this Security, any modification of this
Security, any invalidity, irregularity or unenforceability of this Security or the Indenture, any failure to enforce the same or any waiver, modification, consent or indulgence granted to the Company with respect thereto by the Holder of this
Security or the Trustee, or any other circumstances which may otherwise constitute a legal or equitable discharge of a surety or guarantor. Each Guarantor hereby waives diligence, presentment, demand of payment, filing of claims with a court in the
event of merger or bankruptcy of the Company, any right to require a demand or proceeding first against the Company, protest or notice with respect to this Security or the indebtedness evidenced thereby and all demands whatsoever, and covenants that
this Guarantee will not be discharged as to this Security except by payment in full of the principal of (including any amount payable in respect of original issue discount), and interest (together with any Additional Amounts payable pursuant to the
terms of this Security), thereon. 
 Each Guarantor irrevocably waives any and all rights to which it may be entitled, by operation of law
or otherwise, upon making any payment hereunder (i) to be subrogated to the rights of a Holder against the Company with respect to such payment or otherwise to be reimbursed, indemnified or exonerated by the Company in respect thereof or
(ii) to receive any payment, in the nature of contribution or for any other reason, from any other obligor with respect to such payment. 

This Guarantee shall not be valid or become obligatory for any purpose with respect to this Security until the certificate of authentication
on this Security shall have been signed by the Trustee. 

  
 B-1 

 Exhibit B 
  

 All terms used in this Guarantee which are not defined herein shall have the meaning assigned
to them in the Security upon which this Guarantee is endorsed. 
 This Guarantee is subject to the release upon the terms set forth in the
Indenture. 
 This Guarantee is subject to certain limitations and waivers set forth in the Indenture, as it may be supplemented from time
to time. 
 This Guarantee is governed by and construed in accordance with the laws of the State of New York. 

IN WITNESS WHEREOF, each of the undersigned has caused this Guarantee to be signed by facsimile by its duly authorized officer or
representative and, if required by applicable law, has caused a facsimile of its corporate seal to be affixed hereunto or imprinted hereon. 
  

					
	 ANHEUSER-BUSCH INBEV NV/SA

as Parent Guarantor

		
	By:	 	  

		 	Name:	 	
		 	Title:	 	Authorized Officer
		
	By:	 	  

		 	Name:	 	
		 	Title:	 	Authorized Officer
	
	 ANHEUSER-BUSCH INBEV WORLDWIDE INC.

as Subsidiary Guarantor

		
	By:	 	  

		 	Name:	 	
		 	Title:	 	Authorized Officer
	
	 ANHEUSER-BUSCH COMPANIES, LLC

As Subsidiary Guarantor

		
	By:	 	  

		 	Name:	 	
		 	Title:	 	Authorized Officer

  
 B-2 

 Exhibit B 
  

 
					
	 COBREW NV

as Subsidiary Guarantor

		
	By:	 	  

		 	Name:	 	
		 	Title:	 	Authorized Officer
		
	By:	 	  

		 	Name:	 	
		 	Title:	 	Authorized Officer
	
	 BRANDBREW S.A.

as Subsidiary Guarantor

		
	By:	 	  

		 	Name:	 	
		 	Title:	 	Authorized Officer
	
	 BRANDBEV S.À R.L.

as Subsidiary Guarantor

		
	By:	 	  

		 	Name:	 	
		 	Title:	 	Authorized Officer

  
 B-3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]